Ella Jeffries / beckershospitalreview - Moderna has received a refusal-to-file letter from the FDA’s Center for Biologics Evaluation and Research for its biologics license application for mRNA-1010, its investigational seasonal influenza vaccine. The letter, signed by Vinayak Prasad, MD, chief …
AI Summary: Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making.
FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 1 month
FDA launches individualized therapy framework for ultra-rare diseases / 3 months
FDA makes one pivotal trial the default for drug approvals / 3 months
FDA rejects Atara cell therapy for Epstein–Barr virus complications / 4 months
Boehringer gains fast approval for first‑line lung cancer drug via voucher program / 3 months
FDA commissioner Marty Makary resigns amid mounting scrutiny / 19 days
World Cancer Day Global Awareness Campaign / 3 months
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.